Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of quinine and pharmaceutically acceptable salts thereof to preparation of drug for treating AD (atopic dermatitis)

A technology for atopic dermatitis and drugs, applied in the field of medicine, can solve problems such as benign malaria that cannot be cured, and achieve the effects of expanding medical applications, reducing the area of ​​skin lesions, and reducing pathological damage

Active Publication Date: 2020-06-19
SHENZHEN UNIV +1
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Quinine has no effect on the infrared phase and cannot cure benign malaria. Long-term treatment can cure falciparum malaria, but it has no direct effect on the gametocytes of falciparum malaria, so it cannot interrupt the transmission
There is no relevant report about quinine in the field of atopic dermatitis treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of quinine and pharmaceutically acceptable salts thereof to preparation of drug for treating AD (atopic dermatitis)
  • Application of quinine and pharmaceutically acceptable salts thereof to preparation of drug for treating AD (atopic dermatitis)
  • Application of quinine and pharmaceutically acceptable salts thereof to preparation of drug for treating AD (atopic dermatitis)

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0048] 1. Experimental method

[0049] 1.1 Experimental grouping

[0050] 24 experimental mice were randomly divided into 4 groups, 6 in each group, which were control group, low-dose group, middle-dose group and high-dose group, which were recorded as group A, group B, group C and group D in turn.

[0051] 1.2 Establishment of AD mouse model

[0052] Shave the back body hair of the mice (use an electric shaver to shave the back long hair first, then apply a layer of depilatory cream, wait for about 3-5 minutes, then soak the gauze with physiological saline and wipe it gently, after the depilation is completed, use a dry Dry the back skin and surrounding hair with gauze), with an area of ​​2.5cm×2.5cm, apply 0.5% DNFB on the back of the mouse (absorb 100μl 0.5% DNFB with a 100μl pipette gun), and apply it in small amounts (2-3 times) on the back of the mouse On the depilated area (the drug will be dispersed automatically), apply once a day for 28 consecutive days. AD manife...

experiment example 2

[0063] 1. Experimental method

[0064] 1.1 Experimental grouping

[0065] Twelve experimental mice were randomly divided into two groups, 6 in each group, which were the control group and the experimental group, which were recorded as group A and group B, respectively.

[0066] 1.2 Establishment of AD mouse model

[0067] Same as experimental example 1.

[0068] 1.3 Administration method

[0069] Preparation of the test product: Dissolve quinine in physiological saline so that the concentration of quinine is 10 mg / kg.

[0070] From the 29th day of the experiment, the model mice in each group were treated as follows:

[0071] The model mice in group A were smeared with normal saline on the skin lesion area, once a day, 100 μL each time; the model mice in group B were smeared with the test product on the skin lesion area once a day, 100 μL each time, and each group was treated continuously 7 days.

[0072] 1.4 Histopathological examination of skin lesions

[0073] The spe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, in particular to an application of quinine and pharmaceutically acceptable salts thereof to preparation of a drug for treating AD (atopic dermatitis) and the drug for treating AD. A mouse model of AD is established by an embodiment, a skin lesion region of a mouse is smeared with a physiological saline solution of quinine, and the skin lesion is found to be obviously reduced. Further research shows that quinine can obviously reduce the pathological injury of the mouse, activate expression of a bitter taste receptor and silk polymerization protein, inhibit IgE in blood of the mouse and secretion of cytokines such as IL-1beta, IL-4, IL-5, IL-13 and IL-33 in skin lesion tissue, and thus, improve the skin condition, enhance the skin barrier function, inhibit occurrence of allergic reaction, relieve skin damage caused by immune reaction, and play a safe and effective role in treating the skin damage caused by AD. The invention expands medicalapplications of quinine and provides a new direction for treatment of AD.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of quinine and a pharmaceutically acceptable salt thereof in preparing a medicine for treating atopic dermatitis, and also relates to a medicine for treating atopic dermatitis. Background technique [0002] Atopic dermatitis (AD), also known as atopic dermatitis, atopic dermatitis, atopic eczema, and Besnier prurigo, is a genetic predisposition caused by epidermal barrier damage and related immune disorders. Skin disorders, most ADs have an onset in early childhood and have an age-dependent distribution, often accompanied by elevated IgE levels, peripheral eosinophilia, and other allergic symptoms. AD lesions in the acute phase are mainly caused by Th2 cells and cytokines such as IL-4, IL-5, IL-13, and AD skin lesions in the chronic phase are mainly infiltrated by Th1 cells, which produce IFN-γ, IL- 1β and TNF-β are involved in cell-mediated inflammatory responses and inhibit the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/49A61P17/00A61P17/04A61P37/08A61P29/00
CPCA61K31/49A61K9/0014A61P17/00A61P17/04A61P37/08A61P29/00Y02A50/30
Inventor 王俐张倩严虹吕艳思黄靖凯于娜刘洁孔毅张晓东温字平
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com